Improved SARS-CoV-2 M^pro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies.

ABSTRACT: Replication of SARS-CoV-2, the coronavirus causing COVID-19, requires a main protease (M^pro) to cleave viral proteins. Consequently, M^pro is a target for antiviral agents. We and others previously demonstrated that GC376, a bisulfite prodrug with efficacy as an anti-coronaviral agent in animals, is an effective inhibitor of M^pro in SARS-CoV-2. Here, we report structure-activity studies of improved GC376 derivatives with nanomolar affinities and therapeutic indices >200. Crystallographic structures of inhibitor-M^pro complexes reveal that an alternative binding pocket in M^pro, S4, accommodates the P3 position. Alternative binding is induced by polar P3 groups or a nearby methyl. NMR and solubility studies with GC376 show that it exists a

SUBMITTER: Vuong W 

PROVIDER: S-EPMC8164773 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature